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Chryseobacterium indologenes was isolated from the blood cultures of an oncological patient with a totally implantable device. Because a
catheter-related infection was suspected, the Port-A-Cath1 was removed after a 10-day course of piperacillin–tazobactam.
Differences in susceptibility may exist if either the criteria for either Pseudomonas or Enterobacteriaceae are used.
INTRODUCTION
Totally implantable intravascular devices are used to administer
drugs to patients with a malignant disease. These devices offer
the advantage of improved patient image and obviate the need
for routine catheter-site care. However, pathogenic and oppor-
tunistic bacteria can contaminate indwelling catheters, espe-
cially in the hospital environment. The device can then become
a reservoir for further dissemination of the bacteria. We report a
case of an oncology patient with a totally implantable intra-
vascular device (Port-A-Cath1, PAC) that became contami-
nated with Chryseobacterium indologenes.
CASE REPORT
In October 1999, a 38-year-old woman was diagnosed with
bone and liver metastases of an already locally and regionally
advanced breast cancer. Because of the severity of the hyper-
calcemia and associated symptoms (the patient underwent a
successful resuscitation because of ventricular fibrillation),
urgent renal dialysis was performed. Two weeks later a
chemotherapeutic regimen of CAF (cyclophosphamide–
adriamycine5-fluorouracyl) together with biphosphonates
was started in a day-patient setting. The drugs were adminis-
tered through the PAC on days 1 and 8, and repeated every
28 days. On day 8 of this first cycle the patient was urgently
admitted to the hospital because of a relapsing hypercalcemia.
Laboratory investigations revealed no neutropenia. Within half
an hour after manipulation of the PAC she experienced a fever
of 39 8C. Apart from the tumor in the right breast, physical
examination revealed no abnormalities. The patient was started
on a combination of intravenous piperacillin and tazobactam
(4 4 g IV daily).
One day after blood cultures were taken, bacterial growth
was detected with a Bactec 9240 (Becton Dickinson Diagnostic
Instruments System, Sparks, MD, USA) in the aerobic blood
culture bottles (BactecTM Plus Aerobic) collected from two
different samples. The first sample was through a venous
puncture; the second sample was through the PAC of the
patient. The anaerobic blood bottles cultured negative.
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The Gram stain showed Gram-negative bacilli. On the
second day, two types of colonies appeared: the first strain
was identified as Acinetobacter lwoffii; the second strain grew on
conventional agar media but did not grow on MacConkey agar.
Chryseobacterium was suspected but the conventional tests
could not make a differentiation to the species level after
72 h of incubation. With the BBL1 CrystalTM Enteric/non-
fermenter identification system (Becton Dickinson Diagnostic
Instruments System), C. indologenes was identified (code
2301110112; oxidase-positive, indole-negative) with a prob-
ability of 70.3%. The strain was sent to a reference laboratory
(Prof. Wauters, Cliniques Universitaires, St-Luc, Woluwe,
Belgium) for further identification and confirmation.
Antimicrobial susceptibility testing was performed with the
disc diffusion method according to NCCLS [1]. For interpreta-
tion we used the zone diameters for Pseudomonas aeruginosa. The
strain was resistant to ampicillin, amoxycillin–clavulanate, cefa-
zolin, cefuroxime, aztreonam, ceftriaxone, amikacin, doxycy-
cline, colistin and meropenem. The strain was susceptible to
piperacillin, piperacillin–tazobactam, ceftazidime, ofloxacin
and trimethoprim–sulfamethoxazole. Additional E test suscept-
ibility testing was performed, in accordance with the manu-
facturer’s directions, for piperacillin, piperacillin–tazobactam,
ceftazidime and ciprofloxacin. The minimum inhibitory con-
centration (MIC) breakpoints of the NCCLS for ‘other non-
Enterobacteriaceae’ were used. The strain was susceptible to the
four antimicrobials tested, with a MIC of 4 mg/L for piper-
acillin (S	 16 mg/L) and piperacillin–tazobactam (S	 16 mg/
L), 3 mg/L and 0.5 mg/L for ceftazidime (S	 8 mg/L) and
ciprofloxacin (S	 1 mg/L), respectively.
After 2 days of intravenous antimicrobial treatment, the fever
subsided totally. Intravenous antimicrobial treatment was given
for 10 days. However, 6 days after the completion of antimi-
crobial treatment, the fever recurred. Bacterial growth was
detected in the aerobic culture blood bottle, taken through
the PAC, while blood taken from a venous puncture cultured
negative. The Gram stain showed Gram-negative bacilli. This
strain had the same morphological and biochemical character-
istics and susceptibility results and was identified as C. indolo-
genes. In view of the suspicion of catheter-related septicemia, the
PAC device was removed. The PAC cultured negative, probably
because only the external part of the device was rinsed with
tryptic soy broth. Thereafter the patient was given an additional
7-day course of pefloxacin (2 400 mg IV daily). To date she
has not experienced any recurrence of fever. The chemother-
apeutic regimen was continued and we noticed a good response.
DISCUSSION
C. indologenes is not part of the human flora but is found in soil,
water, plants and foodstuffs [2]. In the hospital environment, the
bacterium is found in water and on wet surfaces. Indwelling
vascular catheters, feeding tubes and other fluid-associated
equipment may become reservoirs for chryseobacteria [2].
The bacteria can easily survive in the biofilm and resist
antimicrobial treatment [3]. Our patient was treated in a
day-patient setting, where hygienic measures may be less
stringent. The drugs were administered through the PAC,
which probably favored the infection. Chryseobacteria are
non-fastidious, oxidase-positive Gram-negative rods that do
not ferment glucose. They are readily distinguished from
other non-fermenters by their ability to produce indole in
tryptophan broth, but the reaction often is weak and difficult
to demonstrate [4].
Despite their low virulence, chryseobacteria are inherently
resistant to many antimicrobial agents, which makes them
potential candidates for nosocomial infections [5]. Piperacillin,
ofloxacin and ciprofloxacin are potential drugs of choice for the
treatment of infections caused by chryseobacteria [6]. It has
been shown that susceptibility disc diffusion testing is inaccurate
for these organisms, since there is often a poor correlation
between the disc diffusion results and the MIC values [5,7]. The
reason for this remains unclear. Hence, the susceptibility of the
organism cannot be predicted accurately from the disc diffusion
method alone. Usually the zone diameters for Pseudomonas
aeruginosa or Enterobacteriaceae for the disc diffusion results
described by the NCCLS are used, but differences in suscept-
ibility may occur [1,5,6]. An attempt to determine disc diffusion
zone diameters for chryseobacteria has been made by Chang et
al. [6]. According to the zone diameters used in their study, our
strain would have been susceptible to piperacillin and piper-
acillin–tazobactam. The MIC breakpoints for chryseobacteria
have not yet been established by the NCCLS [1,6]. We used the
MIC breakpoints for ‘other non-Enterobacteriaceae’ [1]. The
E test may be an alternative to the standard agar dilution method
for testing susceptibility to ciprofloxacin and ceftazidime but
not to piperacillin, since there may be discrepancies between the
E test result and the standard agar dilution MIC for piperacillin
[5,7].
CONCLUSIONS
The reappearance of the bacterium in the blood cultures 6 days
after completion of the first antimicrobial treatment was sug-
gestive of indwelling device-related infection. The blood cul-
ture taken through the PAC cultured positive, while the venous
blood puncture cultured negative. Generally it is accepted that
the device should be removed if clinical symptoms do not
improve after appropriate antimicrobial therapy [3]. However,
successful treatment of indwelling device-related infections
caused by C. indologenes without removal of the device have
been reported [3]. An alternative treatment option is the
antibiotic lock technique in which a high concentration of an
antibiotic is delivered and locked into the device. This technique
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may be beneficial to treat totally implantable intravascular
device-related septicemia, but few reports have been published
so far [8].
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